Clearside Biomedical Stock (NASDAQ:CLSD)
Previous Close
$1.31
52W Range
$0.65 - $2.12
50D Avg
$1.11
200D Avg
$1.26
Market Cap
$97.54M
Avg Vol (3M)
$244.78K
Beta
2.35
Div Yield
-
CLSD Company Profile
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
CLSD Performance
Peer Comparison
| Ticker | Company |
|---|---|
| GRCL | Gracell Biotechnologies Inc. |
| NUVB | Nuvation Bio Inc. |
| NXTC | NextCure, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| TNYA | Tenaya Therapeutics, Inc. |
| ERAS | Erasca, Inc. |
| SNSE | Sensei Biotherapeutics, Inc. |
| INBX | Inhibrx, Inc. |
| GBIO | Generation Bio Co. |
| OCUL | Ocular Therapeutix, Inc. |
| GRPH | LENZ Therapeutics, Inc. |
| KRON | Kronos Bio, Inc. |
| INZY | Inozyme Pharma, Inc. |
| ORIC | ORIC Pharmaceuticals, Inc. |
| CCCC | C4 Therapeutics, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| EYEN | Eyenovia, Inc. |
| DSGN | Design Therapeutics, Inc. |
| EPIX | ESSA Pharma Inc. |
| DRTS | Alpha Tau Medical Ltd. |
| LYRA | Lyra Therapeutics, Inc. |
| MACK | Merrimack Pharmaceuticals, Inc. |